Vischer advised Haya Therapeutics, a Swiss biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics, which announced a multi-year agreement with Eli Lilly and Company to apply Haya’s advanced RNA-guided regulatory genome platform to